UroGen Pharma Ltd.

What they do

UroGen develops and commercializes treatments for urothelial and specialty cancers using its proprietary RTGel reverse-thermal hydrogel, which is liquid at lower temperatures and gels at body temperature to extend drug dwell time in the urinary tract. Its approved products are Jelmyto (mitomycin) for pyelocalyceal solution for low-grade upper tract urothelial cancer and Zusduri (mitomycin) for intravesical solution for recurrent low-grade intermediate risk non-muscle invasive bladder cancer. Both are instilled via standard catheters or nephrostomy tubes. The pipeline includes UGN-103, UGN-104, and an investigational oncolytic virus, UGN-501.

Revenue drivers

• Zusduri (intravesical mitomycin) — Net product revenue was $50.4 million in Q2 2026, up 73% quarter-over-quarter; launched for recurrent low-grade intermediate risk NMIBC and now the larger of the two commercial products.
• Jelmyto (pyelocalyceal mitomycin) — Net product revenue was $22.0 million in Q2 2026 versus $24.2 million in Q2 2025; full-year 2026 guidance is $97 million to $101 million.
• Pipeline (UGN-103, UGN-104, UGN-501) — UGN-103 is on track for NDA submission in Q3 2026; UGN-501 is expected to begin a Phase 1 trial in Q4 2026; none currently generate revenue.

Recent performance

Second quarter 2026 total revenue was $72.5 million, up from $51.0 million in Q1 2026 and $27.5 million in Q3 2025. Zusduri contributed $50.4 million and Jelmyto $22.0 million in Q2 2026. As of June 30, 2026, there were 1,444 activated sites of care, 452 unique Zusduri prescribers, and 204 repeat prescribers (~45% of total, up from 40% in Q1). Annual revenue grew from $48.0 million in 2021 to $109.8 million in 2025, while net loss widened to $153.5 million in 2025. Operating cash flow was negative $162.4 million in 2025.

Strategy

Management is focused on the commercial launch of Zusduri and continued commercialization of Jelmyto, supported by expanding prescriber adoption and community practice penetration. The company is advancing UGN-103 for NDA submission in Q3 2026 and plans to begin Phase 1 development of UGN-501 in Q4 2026. A newly allowed U.S. patent, once issued, is expected to provide protection into July 2044 for Zusduri and UGN-103. A settlement and license agreement with Teva resolves patent litigation over a generic Jelmyto ANDA.

Risks

• Persistent losses and negative cash flow — The company has incurred net losses every year since 2004, including $153.5 million in 2025, and had an accumulated deficit of $959.7 million as of December 31, 2025.
• Negative shareholders' equity — As of June 30, 2026, total liabilities of $385.0 million exceeded total assets of $252.6 million, producing shareholders' equity of negative $132.4 million.
• Debt service and liquidity — Long-term debt was $188.7 million at June 30, 2026, against cash and equivalents of $79.1 million, and the company states its ability to service indebtedness depends on future cash flows.
• Commercial execution risk — Results depend on sustaining Zusduri adoption, where only 45% of the 452 unique prescribers were repeat prescribers as of June 30, 2026, and on Jelmyto remaining within its $97-$101 million 2026 guidance range.

Outlook

Management expects UGN-103 to be submitted for FDA approval in the third quarter of 2026 and UGN-501 to enter a Phase 1 trial in the fourth quarter of 2026. Jelmyto full-year 2026 revenue guidance remains $97 million to $101 million. The company also expects a newly allowed U.S. patent, once issued, to provide protection into July 2044 for Zusduri and UGN-103.